StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 4.4
Power Rank trend -> Falling
07/26/2024 16:00:00 EST
Natera Inc (NTRA)
Industry: Diagnostics & Research
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, NTRA has been trading in a range between $114.44 and $101.15 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
The AI powered stock chart is in a Red zone currently. We would avoid this stock.
Upside / Downside Potential
Natera Inc $NTRA entered a Red zone 7 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $71.2, a potential down side of -30.65% from the recent price of 102.67. The stock is trading 14.18% (potential upside) below its 52 week high of $117.23 and 178.24 % (potential downside) above its 52 week low of $36.90 - based on the recent price.
Company Summary
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
News
| New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell Carcinoma AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncology highlighting the utility of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, for surveillance in Merkel cell carcinoma (MCC). The full study can be found here. MCC is an aggressive skin cancer with high mortality and a recurrence rate of 40% within 5 years.1 MRD testing using a viral. Source: Business Wire Fri, 26 Jul 2024 08:00:00 -0400 Sentiment: Neutral |
| Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Source: Zacks Investment Research Thu, 25 Jul 2024 11:07:34 -0400 Sentiment: Positive |
| Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. Source: Zacks Investment Research Mon, 22 Jul 2024 09:50:30 -0400 Sentiment: Positive |
| Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at the 28th International Conference on Prenatal Diagnosis and Therapy. Hosted by the International Society of Prenatal Diagnosis (ISPD), the conference will take place July 7-10, 2024, in Boston, MA. Below is the list of poster presentations that will be shared at the. Source: Business Wire Wed, 03 Jul 2024 07:00:00 -0400 Sentiment: Neutral |
| Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroesophageal cancer trial, DECIPHER, that will utilize the company's personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer. DECIPHER (Developing ctDNA Guided Adjuvant Therapy for Gastroesophageal Cancer). Source: Business Wire Thu, 27 Jun 2024 07:00:00 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 117.23 52 Week Low: 36.9 Beta: 1.48 50 Day MA: 108.9796 200 Day MA: 79.3889 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0 Qtr Revenue Growth YOY: 0.521 Forward PE: 0 Trailing PE: 0